These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1893 related articles for article (PubMed ID: 20139221)

  • 41. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women.
    Luna J; Plata M; Gonzalez M; Correa A; Maldonado I; Nossa C; Radley D; Vuocolo S; Haupt RM; Saah A
    PLoS One; 2013; 8(12):e83431. PubMed ID: 24391768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
    Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
    J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
    Garland SM; Paavonen J; Jaisamrarn U; Naud P; Salmerón J; Chow SN; Apter D; Castellsagué X; Teixeira JC; Skinner SR; Hedrick J; Limson G; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Del Rosario-Raymundo MR; Catteau G; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Int J Cancer; 2016 Dec; 139(12):2812-2826. PubMed ID: 27541373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
    Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
    Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The first vaccine against cancer: the human papillomavirus vaccine].
    Bősze P
    Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
    Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
    Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
    J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
    Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
    Villa LL; Costa RL; Petta CA; Andrade RP; Ault KA; Giuliano AR; Wheeler CM; Koutsky LA; Malm C; Lehtinen M; Skjeldestad FE; Olsson SE; Steinwall M; Brown DR; Kurman RJ; Ronnett BM; Stoler MH; Ferenczy A; Harper DM; Tamms GM; Yu J; Lupinacci L; Railkar R; Taddeo FJ; Jansen KU; Esser MT; Sings HL; Saah AJ; Barr E
    Lancet Oncol; 2005 May; 6(5):271-8. PubMed ID: 15863374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancers attributable to human papillomavirus infection.
    Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
    Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys.
    Rob F; Tachezy R; Pichlík T; Rob L; Kružicová Z; Hamšíková E; Šmahelová J; Hercogová J
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27723194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
    Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
    Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
    Ault KA;
    Lancet; 2007 Jun; 369(9576):1861-1868. PubMed ID: 17544766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
    Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
    Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
    Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
    Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.
    Brotherton JM; Kaldor JM; Garland SM
    Sex Health; 2010 Sep; 7(3):310-9. PubMed ID: 20719220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.
    Denny L; Kuhn L; Hu CC; Tsai WY; Wright TC
    J Natl Cancer Inst; 2010 Oct; 102(20):1557-67. PubMed ID: 20884893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 95.